Cargando…

Current trials in erythropoietic protoporphyria: are placebo controls ethical?

A new active substance called “dersimelagon” (MT-7117) is being tested as an alternative treatment option for Erythropoietic protoporphyria (EPP). At the moment, dersimelagon is being tested both in the US and in Europe in a phase III placebo-controlled RCT. However, given the availability of an alr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barman-Aksözen, Jasmin, Andreoletti, Mattia, Blasimme, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Position Statement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580501/ https://www.ncbi.nlm.nih.gov/pubmed/37845740 http://dx.doi.org/10.1186/s13023-023-02941-w

Ejemplares similares

Heme Biosynthetic Gene Expression Analysis With dPCR in Erythropoietic Protoporphyria Patients
por: Granata, Francesca, et al.
Publicado: (2022)

Erythropoietic protoporphyria
por: Lecha, Mario, et al.
Publicado: (2009)

Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other Rare Diseases: A Patient-Initiated EQ-5D Feasibility Study
por: Barman-Aksözen, Jasmin, et al.
Publicado: (2023)

Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide – a three years observational study
por: Barman-Aksözen, Jasmin, et al.
Publicado: (2020)

Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice
por: Barman-Aksözen, Jasmin, et al.
Publicado: (2017)

Microcytosis in Erythropoietic Protoporphyria
por: Graziadei, Giovanna, et al.
Publicado: (2022)

Delivery of oligonucleotides to bone marrow to modulate ferrochelatase splicing in a mouse model of erythropoietic protoporphyria
por: Halloy, François, et al.
Publicado: (2020)

How I treat erythropoietic protoporphyria and X-linked protoporphyria
por: Leaf, Rebecca Karp, et al.
Publicado: (2023)

The role of ClpX in erythropoietic protoporphyria
por: Whitman, Jared C., et al.
Publicado: (2018)

UK experience of liver transplantation for erythropoietic protoporphyria
por: Dowman, Joanna K., et al.
Publicado: (2011)

Laparoscopic Cholecystectomy in a Patient with Erythropoietic Protoporphyria
por: Roe, Thomas, et al.
Publicado: (2010)

Advances in the management of erythropoietic protoporphyria – role of afamelanotide
por: Lane, Ashley M, et al.
Publicado: (2016)

Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria
por: Dickey, Amy K., et al.
Publicado: (2020)

A pilot study of oral iron therapy in erythropoietic protoporphyria and X-linked protoporphyria
por: Balwani, Manisha, et al.
Publicado: (2022)

Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders
por: Mulberg, Andrew E., et al.
Publicado: (2019)

Results of the 2018 Japan Society for Blood Purification in Critical Care survey: current status and outcomes
por: Abe, Masanori, et al.
Publicado: (2022)

Model organisms contribute to diagnosis and discovery in the undiagnosed diseases network: current state and a future vision
por: Baldridge, Dustin, et al.
Publicado: (2021)

The SMA Clinical Trial Readiness Program: creation and evaluation of a program to enhance SMA trial readiness in the United States
por: Peterson, Ilse, et al.
Publicado: (2020)

Recommendations for the design of small population clinical trials
por: Day, Simon, et al.
Publicado: (2018)

Cross-cutting view of current challenges in paediatric solid organ and haematopoietic stem cell transplantation in Europe: the European Reference Network TransplantChild
por: Jara, P., et al.
Publicado: (2020)

Erythropoietic protoporphyria: case reports for clinical and therapeutic hints
por: Tumminelli, Cristina, et al.
Publicado: (2023)

An Unusual Case of Erythropoietic Protoporphyria Mimicking Lipoid Proteinosis
por: Kaur, Sarabjit, et al.
Publicado: (2019)

Erythropoietic Protoporphyria-related Hepatopathy Successfully Treated with Phlebotomy
por: Yoshida, Akihiro, et al.
Publicado: (2018)

Recognized and Emerging Features of Erythropoietic and X-Linked Protoporphyria
por: Di Pierro, Elena, et al.
Publicado: (2022)

Erythropoietic protoporphyria: Delayed presentation with decompensated liver disease
por: Sarda, Radhika, et al.
Publicado: (2020)

Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III
por: Ghosh, Arunabha, et al.
Publicado: (2017)

Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X‐linked protoporphyria
por: Naik, Hetanshi, et al.
Publicado: (2019)

Directions for new developments on statistical design and analysis of small population group trials
por: Hilgers, Ralf-Dieter, et al.
Publicado: (2016)

Disease modifying treatment trials in Parkinson’s disease: how to balance expectations and interests of patients, physicians and industry partners?
por: Berg, D., et al.
Publicado: (2020)

Regulation of Glucose Control in People with Type 2 Diabetes: A Review and Consensus
por: Woo, Jeong-Taek, et al.
Publicado: (2010)

Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease
por: Spineli, Loukia M., et al.
Publicado: (2017)

A plea to provide best evidence in trials under sample-size restrictions: the example of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients
por: Lasch, Florian, et al.
Publicado: (2017)

Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria
por: Manti, Filippo, et al.
Publicado: (2022)

Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study
por: Minder, Anna-Elisabeth, et al.
Publicado: (2021)

eHealth for patients with rare diseases: the eHealth Working Group of the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN)
por: Paglialonga, Alessia, et al.
Publicado: (2021)

Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes
Publicado: (2016)

Prevention of photosensitivity with action spectrum adjusted protection for erythropoietic protoporphyria
por: Teramura, Takashi, et al.
Publicado: (2017)

The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria
por: Wang, Pengcheng, et al.
Publicado: (2019)

Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement
por: Leshem, Y.A., et al.
Publicado: (2019)

European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants
por: van de Laar, Ingrid M. B. H., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_emnqujjerkivrjc0envm1ogvd5